Foreign Pharmas Vow To Fight Korean Profit-Taking Bill
This article was originally published in PharmAsia News
Executive Summary
Foreign pharma firms are stepping up their efforts to curb an “unprecedented” bill that would enable the South Korean government to collect what it considers unfair profits taken by original drug makers under a newly implemented drug patent-approval linkage system.